Couillard Simon, Connolly Clare, Borg Catherine, Pavord Ian
Respiratory Medicine Unit and Oxford Respiratory NIHR BRC, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke, QC, Canada.
Obstet Med. 2021 Sep;14(3):135-144. doi: 10.1177/1753495X20965072. Epub 2020 Nov 1.
To update obstetric care providers about asthma management.
Asthma is the most frequent comorbid chronic illness in pregnancy. Convincing evidence shows that uncontrolled asthma magnifies the risk of maternal, fetal and neonate complications. Unfortunately, one in four women take no inhaler during pregnancy, and it is likely that decreased adherence, rather than changes in pathology, explains uncontrolled maternal asthma. Patient surveys reveal a need for information and reassurance. Although some molecules are preferred in pregnancy, there is currently no basis to withhold any asthma medication - old or new. Biomarkers such as blood eosinophils and fractional exhaled nitric oxide are an effective way to assess the risk of asthma attacks and the likelihood of responding to inhaled steroids. Furthermore, practice-changing trials in mild asthma show that switching reliever-only regimens to as-needed 'controller-and-reliever' therapy is effective. We suggest that applying these changes can alleviate women's concerns and improve outcomes.
向产科护理人员介绍哮喘管理的最新情况。
哮喘是孕期最常见的合并慢性疾病。有力证据表明,未得到控制的哮喘会增加孕产妇、胎儿和新生儿并发症的风险。不幸的是,四分之一的女性在孕期不使用吸入器,而孕产妇哮喘未得到控制很可能是由于依从性降低,而非病理变化所致。患者调查显示她们需要信息和安慰。虽然孕期有些药物更受青睐,但目前没有理由停用任何哮喘药物,无论是旧药还是新药。血液嗜酸性粒细胞和呼出一氧化氮分数等生物标志物是评估哮喘发作风险和对吸入性类固醇反应可能性的有效方法。此外,针对轻度哮喘的改变治疗方式的试验表明,将仅使用缓解药物的治疗方案改为按需使用“控制药物和缓解药物”的治疗方法是有效的。我们建议采用这些改变可以减轻女性的担忧并改善治疗结果。